ID   CR1L_RAT                Reviewed;         559 AA.
AC   Q63135; Q63612;
DT   30-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   24-JUL-2024, entry version 149.
DE   RecName: Full=Complement component receptor 1-like protein;
DE   AltName: Full=Antigen 5I2;
DE   AltName: Full=Complement regulatory protein Crry;
DE   Flags: Precursor;
GN   Name=Cr1l; Synonyms=Crry;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Liver;
RX   PubMed=8117286; DOI=10.1006/bbrc.1994.1117;
RA   Sakurada C., Seno H., Dohi N., Takizawa H., Nonaka M., Okada N., Okada H.;
RT   "Molecular cloning of the rat complement regulatory protein, 5I2 antigen.";
RL   Biochem. Biophys. Res. Commun. 198:819-826(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley;
RX   PubMed=7590969; DOI=10.1007/bf00179397;
RA   Quigg R.J., Lo C.F., Alexander J.J., Sneed A.E. III, Moxley G.;
RT   "Molecular characterization of rat Crry: widespread distribution of two
RT   alternative forms of Crry mRNA.";
RL   Immunogenetics 42:362-367(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 39-53; 66-74; 369-373 AND 520-528 (ISOFORM 1),
RP   INTERACTION WITH C3B, AND FUNCTION.
RX   PubMed=8144902;
RA   Takizawa H., Okada N., Okada H.;
RT   "Complement inhibitor of rat cell membrane resembling mouse Crry/p65.";
RL   J. Immunol. 152:3032-3038(1994).
RN   [5]
RP   FUNCTION.
RX   PubMed=7534798;
RA   Quigg R.J., Holers V.M., Morgan B.P., Sneed A.E. III;
RT   "Crry and CD59 regulate complement in rat glomerular epithelial cells and
RT   are inhibited by the nephritogenic antibody of passive Heymann nephritis.";
RL   J. Immunol. 154:3437-3443(1995).
RN   [6]
RP   FUNCTION.
RX   PubMed=15474557; DOI=10.1016/j.lfs.2004.06.007;
RA   Antic Stankovic J., Vucevic D., Majstorovic I., Vasilijic S., Colic M.;
RT   "The role of rat Crry, a complement regulatory protein, in proliferation of
RT   thymocytes.";
RL   Life Sci. 75:3053-3062(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-527 AND SER-554, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [8]
RP   3D-STRUCTURE MODELING OF 34-353.
RX   PubMed=12767833; DOI=10.1016/s0022-2836(03)00492-3;
RA   Aslam M., Guthridge J.M., Hack B.K., Quigg R.J., Holers V.M., Perkins S.J.;
RT   "The extended multidomain solution structures of the complement protein
RT   Crry and its chimeric conjugate Crry-Ig by scattering, analytical
RT   ultracentrifugation and constrained modelling: implications for function
RT   and therapy.";
RL   J. Mol. Biol. 329:525-550(2003).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-288, AND DISULFIDE BONDS.
RX   PubMed=21795784; DOI=10.1107/s1744309111016551;
RA   Roversi P., Johnson S., Caesar J.J., McLean F., Leath K.J.,
RA   Tsiftsoglou S.A., Morgan B.P., Harris C.L., Sim R.B., Lea S.M.;
RT   "Structures of the rat complement regulator CrrY.";
RL   Acta Crystallogr. F 67:739-743(2011).
CC   -!- FUNCTION: Acts as a cofactor for complement factor I, a serine protease
CC       which protects autologous cells against complement-mediated injury by
CC       cleaving C3b and C4b deposited on host tissue. Also acts as a decay-
CC       accelerating factor, preventing the formation of C4b2a and C3bBb, the
CC       amplification convertases of the complement cascade. Seems to act as a
CC       costimulatory factor for T-cells. May play a crucial role in early
CC       embryonic development by maintaining fetomaternal tolerance.
CC       {ECO:0000269|PubMed:15474557, ECO:0000269|PubMed:7534798,
CC       ECO:0000269|PubMed:8144902}.
CC   -!- SUBUNIT: Interacts with C3b. {ECO:0000269|PubMed:8144902}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q63135-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q63135-2; Sequence=VSP_019051;
CC   -!- SIMILARITY: Belongs to the receptors of complement activation (RCA)
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D42114; BAA07698.1; -; mRNA.
DR   EMBL; D42115; BAA22548.1; -; mRNA.
DR   EMBL; L36532; AAA91821.1; -; mRNA.
DR   EMBL; BC061736; AAH61736.1; -; mRNA.
DR   PIR; JC2054; JC2054.
DR   RefSeq; NP_001005265.1; NM_001005265.1. [Q63135-2]
DR   RefSeq; NP_001005330.1; NM_001005330.1.
DR   RefSeq; NP_062174.1; NM_019301.2. [Q63135-1]
DR   PDB; 1NTJ; X-ray; 30.00 A; A=34-353.
DR   PDB; 2XRB; X-ray; 2.50 A; A=1-288.
DR   PDB; 2XRD; X-ray; 3.50 A; A=1-288.
DR   PDBsum; 1NTJ; -.
DR   PDBsum; 2XRB; -.
DR   PDBsum; 2XRD; -.
DR   AlphaFoldDB; Q63135; -.
DR   SMR; Q63135; -.
DR   STRING; 10116.ENSRNOP00000074390; -.
DR   GlyCosmos; Q63135; 2 sites, No reported glycans.
DR   GlyGen; Q63135; 2 sites.
DR   iPTMnet; Q63135; -.
DR   PhosphoSitePlus; Q63135; -.
DR   jPOST; Q63135; -.
DR   Ensembl; ENSRNOT00055019167; ENSRNOP00055015442; ENSRNOG00055011303. [Q63135-1]
DR   Ensembl; ENSRNOT00060023870; ENSRNOP00060018997; ENSRNOG00060013940. [Q63135-1]
DR   Ensembl; ENSRNOT00065006698; ENSRNOP00065004621; ENSRNOG00065004529. [Q63135-1]
DR   GeneID; 54243; -.
DR   KEGG; rno:54243; -.
DR   AGR; RGD:2399; -.
DR   CTD; 1379; -.
DR   RGD; 2399; Cr1l.
DR   VEuPathDB; HostDB:ENSRNOG00000008193; -.
DR   eggNOG; KOG4297; Eukaryota.
DR   HOGENOM; CLU_020107_5_2_1; -.
DR   InParanoid; Q63135; -.
DR   OrthoDB; 5395408at2759; -.
DR   PhylomeDB; Q63135; -.
DR   TreeFam; TF334137; -.
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   Reactome; R-RNO-977606; Regulation of Complement cascade.
DR   EvolutionaryTrace; Q63135; -.
DR   PRO; PR:Q63135; -.
DR   Proteomes; UP000002494; Chromosome 13.
DR   Bgee; ENSRNOG00000008193; Expressed in lung and 20 other cell types or tissues.
DR   ExpressionAtlas; Q63135; baseline and differential.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISO:RGD.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0043235; C:receptor complex; ISO:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; ISO:RGD.
DR   GO; GO:0006956; P:complement activation; ISO:RGD.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0007565; P:female pregnancy; IEA:UniProtKB-KW.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0045916; P:negative regulation of complement activation; IMP:RGD.
DR   GO; GO:0045959; P:negative regulation of complement activation, classical pathway; IBA:GO_Central.
DR   GO; GO:0030449; P:regulation of complement activation; ISO:RGD.
DR   GO; GO:1903659; P:regulation of complement-dependent cytotoxicity; ISO:RGD.
DR   GO; GO:0002456; P:T cell mediated immunity; IBA:GO_Central.
DR   CDD; cd00033; CCP; 7.
DR   Gene3D; 2.10.70.10; Complement Module, domain 1; 7.
DR   InterPro; IPR050350; Compl-Cell_Adhes-Reg.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   PANTHER; PTHR19325; COMPLEMENT COMPONENT-RELATED SUSHI DOMAIN-CONTAINING; 1.
DR   PANTHER; PTHR19325:SF545; COMPLEMENT RECEPTOR TYPE 1; 1.
DR   Pfam; PF00084; Sushi; 7.
DR   SMART; SM00032; CCP; 7.
DR   SUPFAM; SSF57535; Complement control module/SCR domain; 7.
DR   PROSITE; PS50923; SUSHI; 7.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complement pathway;
KW   Developmental protein; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Immunity; Innate immunity; Membrane; Phosphoprotein;
KW   Pregnancy; Receptor; Reference proteome; Repeat; Signal; Sushi;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..35
FT                   /evidence="ECO:0000255"
FT   CHAIN           36..559
FT                   /note="Complement component receptor 1-like protein"
FT                   /id="PRO_0000238979"
FT   TOPO_DOM        36..482
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        483..503
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        504..559
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          36..96
FT                   /note="Sushi 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DOMAIN          97..158
FT                   /note="Sushi 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DOMAIN          159..229
FT                   /note="Sushi 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DOMAIN          231..290
FT                   /note="Sushi 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DOMAIN          292..354
FT                   /note="Sushi 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DOMAIN          355..415
FT                   /note="Sushi 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DOMAIN          417..477
FT                   /note="Sushi 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   REGION          535..559
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         527
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         531
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64735"
FT   MOD_RES         537
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64735"
FT   MOD_RES         540
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64735"
FT   MOD_RES         554
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        53
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        331
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        38..81
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        68..94
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        99..140
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        126..156
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        161..210
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        190..227
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        233..275
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        261..288
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:21795784"
FT   DISULFID        294..336
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DISULFID        322..352
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DISULFID        357..400
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DISULFID        386..413
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DISULFID        419..462
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DISULFID        448..475
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   VAR_SEQ         354..415
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8117286"
FT                   /id="VSP_019051"
FT   CONFLICT        66
FT                   /note="Y -> Q (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69
FT                   /note="R -> Q (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          45..51
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          63..68
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          76..81
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          108..114
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          121..126
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          130..134
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          136..143
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          146..151
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          155..158
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          170..173
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          185..190
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          200..204
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          206..222
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          226..229
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          241..243
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          249..252
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          256..261
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          266..269
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          271..276
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   TURN            277..279
FT                   /evidence="ECO:0007829|PDB:2XRB"
FT   STRAND          280..283
FT                   /evidence="ECO:0007829|PDB:2XRB"
SQ   SEQUENCE   559 AA;  61680 MW;  29E10F6A21DB9B6E CRC64;
     MEASSPLDPV GRLVAFCRGG VHLAVLLLFL SPSTLGQCPA PPLFPYAKPI NPTDESTFPV
     GTSLKYECRP GYIKRQFSIT CEVNSVWTSP QDVCIRKQCE TPLDPQNGIV HVNTDIRFGS
     SITYTCNEGY RLIGSSSAMC IISDQSVAWD AEAPICESIP CEIPPSIPNG DFFSPNREDF
     HYGMVVTYQC NTDARGKKLF NLVGEPSIHC TSIDGQVGVW SGPPPQCIEL NKCTPPHVEN
     AVIVSKNKSL FSLRDMVEFR CQDGFMMKGD SSVYCRSLNR WEPQLPSCFK VKSCGAFLGE
     LPNGHVFVPQ NLQLGAKVTF VCNTGYQLKG NSSSHCVLDG VESIWNSSVP VCEQVICKLP
     QDMSGFQKGL QMKKDYYYGD NVALECEDGY TLEGSSQSQC QSDASWDPPL PKCVSQVICK
     LPQDMSGFQK GLQMKKDYYY GDNVALECED GYTLEGSSQS QCQSDASWDP PLPKCVSRSN
     SGLIAGIFIG IIVLILFIIF SYWMIMKFKK RNSTNEKCKE VGIYLNSKED SCVQPQSLLT
     SQENNSTSSP ARNSLTQEV
//
